7月2日，艾伯维公司盘中上涨3.01%，报259.325美元/股，成交额2.19亿美元。
消息面上，公司近期利好密集释放。6月30日，艾伯维宣布Epcoritamab联合来那度胺在复发或难治性弥漫性大B细胞淋巴瘤患者中取得积极三期试验结果；同期Rinvoq获欧盟CHMP积极意见，拟用于治疗重度斑秃及非节段型白癜风。此外，公司以109亿美元收购Apogee Therapeutics的交易持续提振市场信心，该交易旨在强化免疫学管线并布局呼吸领域。叠加Skyrizi儿科适应症获欧盟批准、Maviret急性丙肝适应症获批等多项监管进展，公司产品管线价值获市场重新定价。
（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.